Literature DB >> 10525996

Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration.

I Litvan1, D A Grimes, A E Lang, J Jankovic, A McKee, M Verny, K Jellinger, K R Chaudhuri, R K Pearce.   

Abstract

Progressive supranuclear palsy (PSP) and cortocobasal degeneration (CBD) are often clinically confused with each other because they share a rapid disease progression, parkinsonism that responds poorly or transiently to levodopa therapy, and associated signs (e.g., ocular abnormalities, pyramidal signs and cognitive involvement). To improve the accuracy in diagnosing these disorders, this study examined the clinical features of 51 patients pathologically diagnosed with PSP and CBD. Logistic regression analysis identified two sets of predictors (models) for CBD patients, one consisting of asymmetric parkinsonism, cognitive disturbances at onset and instability and falls at first clinic visit, and the other one of asymmetric parkinsonism, cognitive disturbances at symptom onset and speech disturbances. While PSP patients often had severe postural instability at onset, symmetric parkinsonism, vertical supranuclear gaze palsy, speech and frontal lobe-type features, CBD patients presented with lateralized motor (e.g., parkinsonism, dystonia or myoclonus) and cognitive signs (e.g., ideomotor apraxia, aphasia or alien limb). On the other hand, CBD patients presenting with an alternate phenotype characterized by early severe frontal dementia and bilateral parkinsonism were generally misdiagnosed. PSP patients without vertical supranuclear gaze palsy were misdiagnosed. Recognizing the features which differentiate these disorders and the less obvious disease presentations as well as developing an increased index of suspicion will improve the diagnostic accuracy of these disorders.

Entities:  

Mesh:

Year:  1999        PMID: 10525996     DOI: 10.1007/bf03161075

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Neuropsychiatric aspects of progressive supranuclear palsy.

Authors:  I Litvan; M S Mega; J L Cummings; L Fairbanks
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

Review 2.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

3.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

4.  Arm levitation in progressive supranuclear palsy.

Authors:  C L Barclay; C Bergeron; A E Lang
Journal:  Neurology       Date:  1999-03-10       Impact factor: 9.910

Review 5.  Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study.

Authors:  I Litvan; Y Agid; C Goetz; J Jankovic; G K Wenning; J P Brandel; E C Lai; M Verny; K Ray-Chaudhuri; A McKee; K Jellinger; R K Pearce; J J Bartko
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

6.  Dystonia in progressive supranuclear palsy.

Authors:  C L Barclay; A E Lang
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

7.  Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria.

Authors:  S J Collins; J E Ahlskog; J E Parisi; D M Maraganore
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

Review 8.  Progressive supranuclear palsy revisited.

Authors:  I Litvan
Journal:  Acta Neurol Scand       Date:  1998-08       Impact factor: 3.209

Review 9.  Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

Authors:  J J Hauw; S E Daniel; D Dickson; D S Horoupian; K Jellinger; P L Lantos; A McKee; M Tabaton; I Litvan
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

10.  Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.

Authors:  I Litvan; C A Mangone; A McKee; M Verny; A Parsa; K Jellinger; L D'Olhaberriague; K R Chaudhuri; R K Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

View more
  23 in total

1.  Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome.

Authors:  Naomi Kouri; Melissa E Murray; Anhar Hassan; Rosa Rademakers; Ryan J Uitti; Bradley F Boeve; Neill R Graff-Radford; Zbigniew K Wszolek; Irene Litvan; Keith A Josephs; Dennis W Dickson
Journal:  Brain       Date:  2011-09-20       Impact factor: 13.501

Review 2.  Visual spatial cognition in neurodegenerative disease.

Authors:  Katherine L Possin
Journal:  Neurocase       Date:  2010-06-02       Impact factor: 0.881

3.  Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinson's disease.

Authors:  Mari Miyata; Shingo Kakeda; Yasuko Toyoshima; Satoru Ide; Kazumasa Okada; Hiroaki Adachi; Yi Wang; Yukunori Korogi
Journal:  Neuroradiology       Date:  2019-07-02       Impact factor: 2.804

4.  What are the different initial presentations of frontotemporal dementia?

Authors:  Tiffany W Chow
Journal:  J Mol Neurosci       Date:  2011-05-27       Impact factor: 3.444

Review 5.  Corticobasal degeneration: a pathologically distinct 4R tauopathy.

Authors:  Naomi Kouri; Jennifer L Whitwell; Keith A Josephs; Rosa Rademakers; Dennis W Dickson
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

Review 6.  Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.

Authors:  Gil D Rabinovici; Bruce L Miller
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

7.  Spatial patterns of the tau pathology in progressive supranuclear palsy.

Authors:  Richard A Armstrong; Nigel J Cairns
Journal:  Neurol Sci       Date:  2012-03-13       Impact factor: 3.307

8.  Discrepancy between clinical and pathological diagnoses of CBD and PSP.

Authors:  Toshiki Mizuno; Kensuke Shiga; Yuriko Nakata; Junko Nagura; Taizen Nakase; Yoshihiro Ueda; Yoshiaki Takanashi; Kohji Urasaki; Yumiko Oyamada; Shinji Fushiki; Junji Nishikawa; Masahiro Yasuhara; Kenji Nakajima; Masanori Nakagawa
Journal:  J Neurol       Date:  2005-03-09       Impact factor: 4.849

9.  Corticobasal degeneration.

Authors:  Stephen G Reich; Stephen E Grill
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

10.  Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical regions of eight cases.

Authors:  R A Armstrong; P L Lantos; N J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2007-08-07       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.